There were several clinical reports of combination therapy targeting NF-κB for pancreatic cancer by using NF-κB inhibitors such as a curcumin [21], nafamostat mesilate [22, 23], bortezomib [24], thalidomide [25], and lenalidomide [26]. This evidence concerns the gene NFKB1 and pancreatic neoplasm.